Since its introduction, Dr. Samuel M. Liu, Director of Retina Services at The Princeton Eye Group, has been providing patients with wet macular degeneration with intravitreal injections for the treatment of the abnormal blood vessels that grow underneath the retina in this condition. These medications include Macugen and Lucentis.
Lucentis is a breakthrough treatment for wet AMD that can do more than just help maintain a person’s vision. With Lucentis, people with wet AMD may actually see their vision improve. It is an FDA-approved treatment specifically developed for the treatment of wet AMD.
Wet AMD occurs when abnormal blood vessels grow in the back of the eye. As the blood vessels grow, they can leak blood and fluid, which damage the macula. The macula–which is the center of your retina–plays a key role in your central vision. Lucentis is designed to block abnormal blood vessel growth and leakage. Along with the abnormal growth blood vessels, certain proteins are thought to play a big part in causing wet AMD. Lucentis is a treatment that targets these proteins–preventing them from causing more damage and possibly even reversing their effects.
Many people saw impressive results with Lucentis. In key clinical studies, about 95% of patients treated with Lucenti found that their vision stayed the same and up to 40% of those patients found that their vision significantly improved. However, wet AMD is a chronic condition and there is no cure. But it can become manageable by treating it monthly with Lucentis. If you have a loved one who may have wet macular degeneration, schedule a consultation to see if Lucentis may be an option.